Savara's Whole Company Is a Coin Flip That Lands in November

Here's a fun exercise: find me another $600-million-ish company whose entire existence — every dollar of value, every job, every patent filed through 2041 — comes down to a single letter from a single government agency on a single day. That's Savara Inc. right now. No revenue. No second drug. No plan B. Just molgramostim, one BLA, and a date on the calendar: November 22, 2026.

That date used to be August 22. The FDA pushed it back three months this spring, and Savara — quite reasonably — pointed out that the delay wasn't about safety, efficacy, or manufacturing. Which is true, and which matters, and which also means precisely nothing about what happens on the actual decision day. A polite extension is still an extension. The market shrugged and parked the stock in a $5–$6 range for months, which is Wall Street's way of saying "we have no idea, ask us in November."

The Case For Believing

Strip away the ticker and look at the disease: autoimmune pulmonary alveolar proteinosis has zero approved therapies. None. If molgramostim clears the FDA, it's not fighting for market share — it's creating the market. That's the entire bull case in one sentence, and it's a good one.

It's not just a hopeful story, either. The IMPALA-2 open-label extension data, presented at ATS in May, showed continued improvement in lung function and quality of life over the long haul — not just a flash of efficacy that fades. Regulators in the UK and EU are reviewing in parallel (decisions expected Q4 2026 and Q1 2027, respectively), so this isn't a one-shot FDA bet dressed up as a global story — it's genuinely three shots on three continents in about six months. And Savara just picked up patent protection in Europe and Australia running to 2041, so if this works, it's not a flash-in-the-pan approval, it's a real commercial runway. Piper Sandler slapped a Buy on it in July. The Street's average price target sits north of $10 — nearly double where the stock trades today.

Financially, management did the sensible thing: they built a cash cushion. About $173 million on hand as of June 30, plus up to $150 million more in non-dilutive financing that unlocks if approval comes through. That's a company that planned for the party rather than betting it'll never need the caterer.

The Case For Sobriety

Now the other side of the ledger, because someone has to say it plainly: this company burns roughly $37 million a quarter and has generated exactly $0 in revenue. Ever. The entire valuation is a bet on a regulatory outcome that hasn't happened yet, wrapped around a drug that has never been sold commercially, in a disease so rare that "successful launch" is its own unproven variable — specialized sales infrastructure, payer negotiations, patient-finding, the whole apparatus that a company with no commercial history has never had to build.

And the delay, whatever its stated reason, is still a delay. Markets don't love ambiguity, and the stock's range-bound chop between $5 and $6 for months is the market pricing in exactly that: real optimism, real caution, no conviction either way. Our internal read flags it too — high short interest (north of 15x), a 24-hour drop of over 3% recently that smells like profit-taking after a run, and a "TRIM" call with medium conviction sitting right on top of a bull target of $10.94 and a bear target under $3.50. That's not a typo — that's the honest shape of a binary event. The forecast bands aren't narrowing as we approach the date; they're basically shrugging.

Where That Leaves You

This is not a stock you own for the fundamentals — there aren't any yet. It's a stock you own (or don't) because you have a view on whether the FDA says yes on November 22nd. Everything else — the patents, the cash runway, the parallel EU/UK filings, the ATS data — is context that makes the "yes" scenario more credible and the "no" scenario more painful. None of it changes the fact that Savara is a lottery ticket with really good production values.

If you're in, know what you're in for: a name that could double toward that $10-plus consensus target on approval, or fall toward the low single digits on a rejection or restrictive label. If you're out, at least you'll know exactly why come November — no earnings call required, no revenue guide to parse. Just one letter, one date, one answer.